Artoss has achieved record sales of NanoBone Bone Graft products in 3Q20.
NanoBone Bone Graft is FDA 510(k) cleared for use as a standalone graft, including in spinal fusion, for its ability to create an osteogenic environment that replicates the architecture and chemistry found in natural bone. The products have been used in Europe and the U.S. for more than fifteen years in more than 100,000 clinical cases across all indications. They have been available in the U.S. since 2015.
Paul Byerley, Chief Executive Officer of Artoss, said, “Through perseverance and diligent effort by our sales management and independent distributors, we accomplished record sales for the quarter. Our team’s continued hard work allowed us to achieve this milestone in the middle of a global pandemic. We are especially gratified to see new surgeon users and hospitals embrace the outstanding clinical outcomes and cost savings when using NanoBone as a standalone bone graft substitute.”
Artoss has achieved record sales of NanoBone Bone Graft products in 3Q20.
NanoBone Bone Graft is FDA 510(k) cleared for use as a standalone graft, including in spinal fusion, for its ability to create an osteogenic environment that replicates the architecture and chemistry found in natural bone. The products have been used in Europe and the...
Artoss has achieved record sales of NanoBone Bone Graft products in 3Q20.
NanoBone Bone Graft is FDA 510(k) cleared for use as a standalone graft, including in spinal fusion, for its ability to create an osteogenic environment that replicates the architecture and chemistry found in natural bone. The products have been used in Europe and the U.S. for more than fifteen years in more than 100,000 clinical cases across all indications. They have been available in the U.S. since 2015.
Paul Byerley, Chief Executive Officer of Artoss, said, “Through perseverance and diligent effort by our sales management and independent distributors, we accomplished record sales for the quarter. Our team’s continued hard work allowed us to achieve this milestone in the middle of a global pandemic. We are especially gratified to see new surgeon users and hospitals embrace the outstanding clinical outcomes and cost savings when using NanoBone as a standalone bone graft substitute.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
